Browse by category

Survodutide GLP-1 receptor dual agonist to be assessed in three global Phase III studies for obesity

Boehringer Ingelheim will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III studies for...

Survey finds 50% of post-bariatric surgery patients feel less stress during the holidays

4 hours ago

Journal Watch 18/12/2024

7 hours ago

True You Weight Loss to initiate two clinical trials assessing gastric fundal mucosal ablation

8 hours ago

Weekly Digest